Why the study?
Does spirapril prevent the progression of renal damage compared to a triple antihypertensive combination in hypertensive diabetic rats?
Population
Hypertensive diabetic rats
Comparison
Angiotensin-converting enzyme inhibitor spirapril vs Antihypertensive triple drug combination of…
Design
Preclinical
Authors
Loading...
Supports ACE inhibition for renoprotection in diabetic models independent of BP; leaves open human translation.
Does spirapril prevent the progression of renal damage compared to a triple antihypertensive combination in hypertensive diabetic rats?
ACE inhibition with spirapril prevents glomerulosclerosis and renal hypertrophy more effectively than standard antihypertensive therapy in hypertensive diabetic rats, independent of blood pressure lowering.
Fabris et al. (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: